| Literature DB >> 19561951 |
Sachin S Soni1, Amit P Nagarik, Gopal Kishan Adikey, Anuradha Raman.
Abstract
BACKGROUND: The incidence of acute renal failure (ARF) in the hospital setting is increasing. It portends excessive morbidity and mortality and a considerable burden on hospital resources. Extracorporeal therapies show promise in the management of patients with shock and ARF. It is said that the potential of such therapy goes beyond just providing renal support. The aim of our study was to analyze the clinical setting and outcomes of critically ill ARF patients managed with continuous renal replacement therapy (CRRT). PATIENTS AND METHODS: Ours was a retrospective study of 50 patients treated between January 2004 and November 2005. These 50 patients were in clinical shock and had concomitant ARF. All of these patients underwent CVVHDF (continuous veno-venous hemodiafiltration) in the intensive care unit. For the purpose of this study, shock was defined as systolic BP < 100 mm Hg in spite of administration of one or more inotropic agents. SOFA (Sequential Organ Failure Assessment) score before initiation of dialysis support was recorded in all cases. CVVHDF was performed using the Diapact((R)) (Braun) CRRT machine. The vascular access used was as follows: femoral in 32, internal jugular in 8, arteriovenous fistula (AVF) in 4, and subclavian in 6 patients. We used 0.9% or 0.45% (half-normal) saline as a prefilter replacement, with addition of 10% calcium gluconate, magnesium sulphate, sodium bicarbonate, and potassium chloride in separate units, while maintaining careful monitoring of electrolytes. Anticoagulation of the extracorporeal circuit was achieved with systemic heparin in 26 patients; frequent saline flushes were used in the other 24 patients.Entities:
Keywords: Acute renal failure; continuous renal replacement therapy; sepsis; shock
Year: 2009 PMID: 19561951 PMCID: PMC2700581 DOI: 10.4103/0974-2700.44678
Source DB: PubMed Journal: J Emerg Trauma Shock ISSN: 0974-2700
Age and gender distribution
| Age interval (Years) | Male ( | Female ( |
|---|---|---|
| 20–29 | 2 (6.8) | 4 (19) |
| 30–39 | 2 (6.8) | 0 |
| 40–49 | 5 (17.2) | 2 (9.5) |
| 50–59 | 5 (17.2) | 4 (19) |
| 60–69 | 7 (24.8) | 7 (33.5) |
| >70 | 8 (27.2) | 4 (19) |
| Mean age | 57.06 ± 17.87 | 54.66 ± 20.59 |
FIGURES IN PARENTHESIS INDICATE PERCENTAGE
Figure 1Comorbid illnesses
Etiology of ARF
| 1. Sepsis | 24 (48%) |
| A. Source of infection identified | 21 |
| a. Cystitis | 7 |
| b. Community-acquired pneumonia | 5 |
| c. Ventilator-associated pneumonia | 2 |
| d. Diabetic foot | 2 |
| e. Acute pyelonephritis | 2 |
| f. Liver abscess | 2 |
| g.Cellulitis | 1 |
| B. Source of infection not identified | 3 |
| 2. Hemodynamically mediated renal failure | 18 (36%) |
| A. Cardiogenic shock | 10 |
| B. Pulmonary thromboembolism | 2 |
| C. Acute pancreatitis | 2 |
| D. Postsurgical | 2 |
| E. Hypovolemia | 2 |
| 3. Acute over chronic kidney disease | 8 (16%) |
| A. Drug-induced | 3 |
| B. Infection | 3 |
| C. Contrast nephropathy | 2 |
CVVHDF details
| Mean duration (h) | 37.51 ± 19.37 (2–168) |
| Mean clearance rate (ml/h) | 1650 ± 75 (1550–1800) |
| Vascular access | |
| Femoral vein | 32 (64%) |
| Internal jugular vein | 8 (16%) |
| Subclavian vein | 6 (12%) |
| AVF | 4 (08%) |
| Anticoagulation | |
| Heparin | 26 (52%) |
| No anticoagulation | 24 (48%) |
Factors influencing mortality by univariate analysis
| Factor | Survivors | Non survivors | |
|---|---|---|---|
| Mean age (Years) | 43.33 ± 15.19 | 56.16 ± 16.3 | 0.04 |
| Gender | Comparing between A and B, NS | ||
| A. Male ( | 8 (27.5%) | 21 (72.5%) | |
| B. Female ( | 5 (23.8%) | 16 (76.2%) | |
| Systolic blood pressure (mmHg) | 97.33 ± 7.50 | 92.45 ±12.5 | NS |
| Diastolic blood pressure (mmHg) | 61.11 ±7.33 | 60.96 ± 8.70 | NS |
| SOFA score | 11.42 ± 3.12 | 15.33 ± 4.01 | 0.03 |
| Serum creatinine (mg/dl) | 4.31 ± 1.00 | 6.93 ± 4.38 | 0.02 |
| Blood urea (mg/dl) | 111.33 ±37.31 | 134.56 ± 65.5 | 0.02 |
| Serum sodium (mEq/l) | 130.54 ±6.93 | 130.70 ±7.07 | NS |
| Serum potassium (mEq/l) | 5.07 ± 0.86 | 4.6l ± 1.22 | NS |
| Blood pH | 7.28 ± 0.09 | 7.13 ± 0.09 | 0.024 |
| Serum bicarbonate (mEq/l) | 18.34 ± 15.25 | 11.96 ± 4.41 | 0.04 |
| Mechanical ventilation | Comparing between A and B, NS | ||
| A. Required ( | 7 (20%) | 28 (80%) | |
| B. Not required ( | 6 (40%) | 9 (60%) |
NS: NOT SIGNIGICANT.
Factors influencing mortality by multivariate analysis
| Variable | Multivariate analysis | ||
|---|---|---|---|
| Odds ratio (OR) | Confidence interval (Cl95%) | ||
| Mean age | 1.65 | 1.35 to 1.92 | 0.04 |
| Male gender (%) | 1.04 | 0.85 to 2.25 | 0.89 |
| SOFA score | 1.25 | 0.94 to 1.96 | 0.16 |
| Serum creatinine | 1.68 | 1.44 to 1.86 | 0.03 |
| Serum bicarbonate | 0.76 | 0.55 to 0.94 | 0.01 |
Mortality in patients treated with CRRT
| Author | Type of study | Number of patients | Mortality in patients treated with CRRT | Remarks |
|---|---|---|---|---|
| Mehta | Randomized trial (CRRT | 84 randomized to CRRT and 82 to IHD | 65.5 | Unadjusted, in hospital mortality |
| Vinsonneau | Multicenter randomized trial (CRRT | 360 patients randomized to CRRT or IHD | 67 | 60-day all-cause mortality |
| Uehlinger | Randomized trial (CRRT | 70 randomized to CRRT and 55 to IHD | 47 | All-cause mortality |
| Lobo[ | Observational study | 22 patients treated with CRRT | 77 | 30-day mortality |
| Our study | Retrospective | 50 patients treated with CRRT | 74 | In-hospital mortality |
IHD: INTERMITTENT HEMODIALYSIS.